Takeda Pharmaceutical Co. Ltd. announced its strategic exit from cell therapy research and development, seeking external partners to advance existing programs. The company is not currently running clinical trials in cell therapies and plans to prioritize near-term investments in small molecules, biologics, and antibody-drug conjugates (ADCs) believed capable of delivering transformative therapies efficiently. This pivot reflects shifting priorities aiming to accelerate pipeline progression and therapeutic impact.